Mogamulizumab-kpkc

{
  "id": "MLC-T-ONC-015234",
  "term": "Mogamulizumab-kpkc",
  "field": "Oncology and biomedicine",
  "definition": "A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.",
  "synonyms": [
    "mogamulizumab",
    "immunoglobulin G1, anti-(CC chemokine receptor CCR4) (human-mouse monoclonal KW-0761 heavy chain), disulfide with human-mouse monoclonal KW-0761 kappa-chain, dimer"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mogamulizumab-kpkc/"
}